|
Forecast Period
|
2026-2030
|
|
Market Size (2024)
|
USD 207.07 Million
|
|
Market Size (2030)
|
USD 306.81 Million
|
|
CAGR (2025-2030)
|
6.73%
|
|
Fastest Growing Segment
|
Antidepressants
|
|
Largest Market
|
Kanto
|
Market Overview
Japan Major Depressive Disorder (MDD) Market was valued
at USD 207.07 Million in 2024 and is expected to reach USD 306.81 Million
by 2030 with a CAGR of 6.73% during the forecast period. The Japan Major
Depressive Disorder (MDD) Market is influenced by several key factors.
Increasing awareness and reduced stigma surrounding mental health issues are
leading to higher diagnosis rates and demand for treatments. The country’s
aging population, which is more prone to depression, significantly contributes
to market growth. Advances in antidepressant medications, psychotherapy, and
digital health technologies also play a crucial role, providing more effective
and accessible treatment options. The Japanese government’s initiatives to
enhance mental health support and integrate mental health services into primary
care are further driving market expansion. Rising healthcare spending and the
adoption of telemedicine are also improving access to care, thereby supporting
market growth.
Key Market Drivers
Increasing Awareness and Decreasing Stigma
The growing awareness of mental health issues in
Japan is a crucial driver of the Japan Major Depressive Disorder (MDD) Market,
marking a significant shift from the historically stigmatized approach towards
mental health. For many years, mental health disorders, including depression,
were subject to societal stigma in Japan, where mental illness was often
associated with personal weakness or failure. This stigma led to widespread
underreporting of mental health issues and a reluctance among individuals to
seek professional help. Such attitudes created barriers to diagnosis and
treatment, leaving many individuals with untreated or inadequately managed
depression. Recent societal shifts, however, have significantly altered the
landscape of mental health in Japan. Increased awareness and education have
been pivotal in transforming public perceptions. Public health campaigns and
media coverage have played a substantial role in highlighting the prevalence of
mental health disorders and the importance of seeking treatment. These efforts
have been complemented by educational programs that aim to reduce stigma,
increase understanding of mental health issues, and provide information about
available treatments. The normalization of mental health discussions in
mainstream media and public forums has fostered a more supportive environment
for individuals grappling with depression. According to an article, major
depression (Major Depressive Disorder [MDD]) is a prevalent, costly, and
diverse psychiatric condition that impacts social functioning and is linked to increased
mortality. In Japan, the 12-month prevalence of major depressive episodes is
2.2%, which is lower than in high-income countries such as the US (8.3%),
France (5.9%), and Germany (3.0%). However, it is believed that the actual
prevalence of MDD in Japan may be higher than reported, as the condition is
often underdiagnosed and consequently inadequately treated or left untreated.
The lower treatment rates for MDD in Japan compared to Western high-income
countries may be partly attributed to the stigma associated with mental illness
in the country.
As societal attitudes evolve, there is a growing
recognition of mental health as an integral part of overall well-being. This
shift has led to an increase in the number of individuals seeking help for
Major Depressive Disorder, resulting in higher rates of diagnosis. The
increasing acceptance and understanding of mental health issues have also
encouraged more people to engage with mental health services, thereby driving
demand for MDD treatments. This evolving landscape is further reflected in the
expansion of the mental health care sector. The growing number of mental health
professionals, including psychiatrists, psychologists, and counselors, is a
testament to the rising demand for mental health services. There has been a
proliferation of specialized services and treatment options designed to address
the diverse needs of individuals with MDD. The expansion of mental health
services includes the development of new therapies, the integration of mental
health care into primary care settings, and the rise of digital mental health
solutions, such as online therapy and mental health apps.
Aging Population
Japan's rapidly aging population is a pivotal
factor driving the Japan Major Depressive Disorder (MDD) Market, reflecting a
significant demographic shift with profound implications for mental health
care. Japan stands out globally with one of the highest life expectancies, a
trend that has led to a burgeoning elderly population. This demographic
transformation is accompanied by increased prevalence of mental health issues,
particularly depression, among the elderly.
As individuals age, they often encounter multiple
factors that heighten their susceptibility to Major Depressive Disorder. Social
isolation is a significant contributor, as older adults may experience
diminished social interactions due to retirement, the death of peers, or
physical limitations that restrict mobility. This isolation can lead to
feelings of loneliness and a lack of purpose, which are strongly associated
with depressive symptoms. Declining physical health, common in older age, can
exacerbate feelings of helplessness and depression. Chronic illnesses,
decreased mobility, and the gradual loss of independence can all contribute to
a decline in mental well-being. The loss of loved ones, whether through death
or geographical separation, can create a profound sense of grief and
loneliness, further increasing the risk of depression among the elderly.
In response to this demographic shift, the Japan
Major Depressive Disorder (MDD) Market is witnessing a growing demand for
treatments and services specifically designed for older adults. Healthcare
providers and pharmaceutical companies are increasingly focusing on developing
therapies that address the unique needs of this age group. Specialized
antidepressants with formulations tailored for elderly patients, as well as
interventions that consider the complex interplay of physical and mental health
in older adults, are becoming more prevalent. This includes treatments that not
only address depressive symptoms but also consider the side effects and
interactions of medications with other chronic conditions common in the
elderly.
Rising Healthcare Expenditure
Rising healthcare expenditure in Japan is a pivotal
driver of the Japan Major Depressive Disorder (MDD) Market, reflecting a
broader commitment to enhancing mental health care through increased financial
investment. As Japan faces various challenges related to an aging population
and rising chronic health conditions, the government and private sectors are
channeling substantial resources into expanding and improving healthcare
services. This financial infusion is significantly impacting the MDD market by
enabling more comprehensive and innovative approaches to mental health care.
One of the most direct effects of rising healthcare
expenditure is the increased funding available for mental health services,
including the treatment of depression. Historically, mental health services
often faced funding challenges compared to other medical specialties, leading
to gaps in care and limited access to treatment. However, with the current
surge in healthcare investment, there is now greater financial support
dedicated to mental health programs. This funding allows for the expansion of
mental health facilities, the recruitment of additional mental health
professionals, and the enhancement of existing services. As a result, patients
with Major Depressive Disorder (MDD) benefit from more accessible and varied
treatment options, which can include outpatient services, inpatient care, and
specialized therapeutic programs.
Increased healthcare expenditure also drives
innovation in the development of new treatments for MDD. Investment in research
and development (R&D) is crucial for advancing pharmaceutical and
therapeutic options. With higher funding, pharmaceutical companies and research
institutions can undertake more extensive clinical trials and develop novel
antidepressants and therapeutic interventions. This includes the creation of
medications with improved efficacy, fewer side effects, and targeted action
mechanisms, as well as the exploration of alternative treatments such as
ketamine therapy and psychedelic-assisted therapy. The focus on R&D fosters
the introduction of cutting-edge treatments that can offer significant benefits
to patients with MDD, thereby enhancing the overall effectiveness of mental
health care.
Focus on Preventive Care and Early Intervention
There is a growing focus on preventive care and
early intervention in the management of Major Depressive Disorder (MDD) in
Japan, which is significantly impacting the Japan Major Depressive Disorder
(MDD) Market. Recognizing the importance of addressing mental health issues
before they escalate, healthcare providers are prioritizing early detection and
intervention strategies. Regular screening for depression is becoming a routine
practice, utilizing validated tools to identify at-risk individuals early.
Educational programs are raising awareness about the early signs of depression
and encouraging timely help-seeking, targeting the general public, healthcare
professionals, and caregivers. Proactive treatment plans are being developed,
combining psychotherapy, medications, and lifestyle interventions to manage
depression before it becomes severe. This shift towards preventive care aims to
reduce the long-term impact of depression, improve patient outcomes, and
enhance overall well-being. As a result, there is increasing demand for
screening tools, early treatment options, and preventive programs, driving
significant growth in the Japan Major Depressive Disorder (MDD) Market.
 Market 1.png)
Download Free Sample Report
Key Market Challenges
Limited Access to Mental Health Services
Access to mental health services is uneven across
Japan, particularly in rural and remote areas. The distribution of mental
health professionals is heavily skewed towards urban centers, leaving many
individuals in less accessible regions without adequate care. This geographic
disparity limits the availability of timely and effective treatment for those
suffering from Major Depressive Disorder (MDD). The shortage of specialized
mental health professionals, such as psychiatrists and psychologists,
exacerbates the problem. Patients in underserved areas may face long wait times
or lack of access to appropriate therapeutic interventions. Addressing these
access issues requires a multifaceted approach, including expanding
telemedicine services, incentivizing mental health professionals to work in rural
areas, and increasing funding for community-based mental health services.
High Cost of Treatment
The cost of treating Major Depressive Disorder
(MDD) can be a significant barrier for many individuals in Japan. While Japan
has a universal healthcare system, the expenses associated with advanced
treatments, medications, and ongoing therapy can still be burdensome for some
patients, especially those with severe depression. The financial strain may
discourage individuals from seeking or continuing treatment, potentially
leading to worsening symptoms and higher long-term costs. Not all mental health
treatments are fully covered by insurance, leading to out-of-pocket expenses
that can deter patients from accessing necessary care. To mitigate this
challenge, it is essential to enhance insurance coverage for mental health
services, explore cost-effective treatment options, and provide financial
support or subsidies for those in need.
Key Market Trends
Advancements in Pharmacological Treatments
The development of new and improved pharmacological
treatments is a pivotal driver of the Japan Major Depressive Disorder (MDD)
Market, reflecting a dynamic shift towards more effective and personalized care
for depression. Recent advancements in antidepressant medications have
significantly impacted the landscape of mental health treatment, offering
patients and healthcare providers a broader array of therapeutic options that
promise better efficacy and fewer side effects compared to older medications. In
November 2020, Biogen Inc. (Nasdaq: BIIB) and Sage Therapeutics, Inc. announced
a global collaboration and licensing agreement to co-develop and commercialize
zuranolone (SAGE-217) for major depressive disorder (MDD), postpartum
depression (PPD), and other psychiatric conditions, as well as SAGE-324 for
essential tremor and various neurological disorders.
Recent innovations have led to the introduction of
novel antidepressants that target specific neurotransmitter systems with
greater precision. Unlike traditional antidepressants, which often have a broad
mechanism of action, these new drugs are designed to interact with particular
neurotransmitter pathways involved in mood regulation. For example, medications
that specifically modulate serotonin and norepinephrine levels or target
glutamate neurotransmission are being developed. These drugs aim to improve
efficacy by addressing the underlying neurochemical imbalances associated with
depression more directly. Advancements have led to the development of antidepressants
with faster onset of action, reducing the waiting period for patients to
experience relief from depressive symptoms. These improvements are critical as
they address one of the major limitations of older antidepressants, which often
take several weeks to show noticeable effects.
The availability of these new pharmacological
treatments significantly enhances the options available to both patients and
healthcare providers. With a more diverse range of medications, healthcare
professionals can tailor treatment plans to individual needs, selecting drugs
that are most likely to be effective based on the specific characteristics of
each patient's depression. This personalization of treatment helps to maximize
therapeutic outcomes and minimize adverse effects. For instance, patients who
have not responded well to traditional antidepressants may benefit from these
novel therapies, which offer alternative mechanisms of action and potentially
better response rates.
Integration of Digital Health Technologies
The integration of digital health technologies is
profoundly transforming the Japan Major Depressive Disorder (MDD) Market,
offering new avenues for delivering care and supporting patients in innovative
ways. This revolution is driven by advancements in telemedicine and digital
mental health platforms, which are enhancing access to treatment, particularly
in remote or underserved areas where traditional mental health services may be
limited or unavailable.
Telemedicine has emerged as a powerful tool in the Japan
Major Depressive Disorder (MDD) Market, breaking down geographical barriers and
providing patients with easier access to mental health care. Through
telemedicine, individuals can connect with mental health professionals via
video consultations, phone calls, or secure messaging platforms, allowing for
remote diagnosis and treatment. This is particularly beneficial for those
living in rural areas or those with mobility issues who might otherwise
struggle to access in-person therapy. Telemedicine not only offers convenience
but also ensures continuity of care, enabling patients to maintain regular
contact with their healthcare providers without the constraints of travel or
location. In parallel, digital mental health platforms have gained traction,
offering a range of services designed to support individuals managing
depression. These platforms include apps and online services that provide
cognitive behavioral therapy (CBT), mood tracking, and virtual consultations.
Apps designed for CBT offer structured programs that patients can follow at
their own pace, providing therapeutic exercises, coping strategies, and
interactive tools to manage symptoms. Mood tracking apps allow individuals to
monitor their emotional state, identify patterns, and share their data with
healthcare providers to inform treatment decisions. Virtual consultation
platforms enable patients to receive counseling and therapy remotely, ensuring
that professional support is accessible regardless of location.
Segmental Insights
Drug Type Insights
Based on the Drug Type, antidepressants
remain the dominant class of treatment, significantly shaping the landscape of
depression management. This dominance is attributed to the established efficacy
of traditional antidepressant medications and their wide acceptance among both
healthcare providers and patients. Antidepressants are primarily used to
balance neurotransmitters in the brain, which are thought to be involved in
mood regulation, and have been the cornerstone of pharmacological treatment for
depression for decades. Among the different classes of antidepressants,
selective serotonin reuptake inhibitors (SSRIs) are particularly prevalent.
SSRIs, such as fluoxetine, sertraline, and paroxetine, are favored for their
favorable safety profile and efficacy. They work by increasing serotonin levels
in the brain, which can help improve mood and alleviate symptoms of depression.
The relative safety of SSRIs compared to older antidepressants, such as
tricyclic antidepressants (TCAs), contributes to their widespread use, as they
generally have fewer side effects and lower toxicity in overdose situations.
This makes them a popular choice among clinicians in Japan when prescribing
medications for MDD.
Application Insights
Based on Application, clinics
are currently the dominant sector compared to hospitals, reflecting a
significant shift in the way mental health care is delivered and accessed. This
dominance is driven by several factors, including the increasing preference for
outpatient care, the evolving landscape of mental health services, and the
efficiency of clinics in managing depression-related treatments. The preference
for outpatient care over inpatient hospitalization has been a significant
factor in the rise of clinics as the dominant sector for MDD treatment.
Clinics, including private psychiatric practices, community mental health
centers, and specialized outpatient facilities, offer a range of services
tailored to managing depression in a non-hospital setting. This trend is driven
by the desire for more accessible, flexible, and less disruptive treatment
options for patients. Outpatient care allows individuals with MDD to receive
therapy and medication management while continuing their daily activities, such
as work and social interactions. This approach aligns with the broader movement
towards patient-centered care, which emphasizes the importance of maintaining a
patient’s quality of life and minimizing disruption.
Clinics provide greater
accessibility and convenience for patients seeking treatment for MDD. With a
widespread network of outpatient facilities, patients can often find a clinic
closer to their home or workplace, reducing travel time and improving the
likelihood of consistent engagement with care. Clinics are typically designed
to offer a range of services, including psychiatric evaluations, psychotherapy,
and medication management, all within a single location. This integrated
approach streamlines the treatment process and makes it easier for patients to
adhere to their treatment plans. The convenience of local access and the
ability to receive care on an outpatient basis contribute to the growing
dominance of clinics in the Japan Major Depressive Disorder (MDD) Market.
 Market 2.png)
Download Free Sample Report
Regional Insights
In the Japan Major Depressive Disorder (MDD)
market, the Kanto region stands out as the dominant area, significantly
influencing the landscape of depression treatment across the country. This
dominance is driven by several factors, including the region’s large population
base, its concentration of healthcare facilities and mental health
professionals, and its robust healthcare infrastructure. The Kanto region,
which includes Tokyo, Yokohama, Chiba, and Saitama, is the most populous region
in Japan. With Tokyo being the capital city and a major metropolitan hub, the
Kanto region is home to a substantial portion of the nation’s population. This
large population base translates to a higher number of individuals experiencing
Major Depressive Disorder (MDD) and consequently, a greater demand for mental
health services. The sheer volume of potential patients drives market growth
and necessitates a wide range of treatment options, making the Kanto region a
central player in the Japan Major Depressive Disorder (MDD) Market. The Kanto
region boasts an extensive network of healthcare facilities and mental health
professionals, contributing to its dominance in the MDD market. Tokyo, as the
epicenter of the region, is home to numerous specialized psychiatric hospitals,
outpatient clinics, and mental health centers. The concentration of healthcare
resources in this region ensures that patients have access to a variety of
treatment options, including advanced pharmacological therapies, psychotherapy,
and innovative digital health solutions. The presence of a high number of
mental health professionals, including psychiatrists, psychologists, and
therapists, enhances the quality of care available and supports the region’s
leading role in managing depression.
The Kanto region's robust healthcare infrastructure
further solidifies its position in the Japan Major Depressive Disorder (MDD)
Market. The region benefits from advanced medical technologies, research
institutions, and a high level of investment in healthcare services. Tokyo, in
particular, serves as a hub for medical research and clinical trials,
contributing to the development and availability of new treatments for MDD. The
presence of major universities and research centers facilitates ongoing
advancements in mental health care, supporting the development and
dissemination of innovative therapies and treatment modalities. The Kanto
region's dominance is also attributed to the availability of advanced treatment
options. The region's healthcare facilities are equipped to offer a wide range
of treatments for MDD, including novel antidepressants, atypical
antidepressants, antipsychotics, and neuromodulators. The integration of
digital health technologies, such as telepsychiatry and digital mental health
platforms, is more prevalent in this region, providing patients with access to
cutting-edge care and continuous support. The variety and sophistication of
treatment options available in the Kanto region contribute to its leading
position in the Japan Major Depressive Disorder (MDD) Market.
Recent Developments
- In December 2023, Otsuka
Pharmaceutical Co., Ltd. (Otsuka) announced that it has received approval in Japan
for an additional indication of Rexulti (generic name: brexpiprazole) for
treating depression or depressive states. This new indication allows for the
use of Rexulti in patients who have not responded adequately to their current
antidepressant therapy. This marks the drug's second approved indication in
Japan, following its initial approval for schizophrenia. A Phase 3 clinical
trial assessed the efficacy and safety of brexpiprazole as an adjunctive
therapy for Major Depressive Disorder in 740 adult patients aged 20 to 64 in
Japan. In this study, brexpiprazole was administered once daily for six weeks
in doses of 1 mg or 2 mg, alongside SSRI or SNRI antidepressants, for patients
who had not responded sufficiently to antidepressant monotherapy. Results showed
that patients receiving brexpiprazole, at both 1 mg and 2 mg doses, exhibited
statistically significant improvements from baseline on the Montgomery-Asberg
Depression Rating Scale compared to those receiving a placebo adjunct.
Brexpiprazole was generally well tolerated, with no new safety concerns
emerging from the trial.
- In June 2023, the
Australia-based biotech startup Psylo has formed a Sponsored Research Agreement
with the global Japanese pharmaceutical firm Daiichi Sankyo to further the
development of psychiatric medicines for individuals dealing with chronic
mental illness. Under this agreement, Psylo will apply its expertise in
neuropsychiatric therapies while benefiting from Daiichi Sankyo's extensive
background in drug discovery and clinical development. This collaboration aims
to advance the research and creation of new treatments for chronic mental
health conditions. Psylo will set up an office within the B+labs incubation
space in Philadelphia, USA, gaining access to state-of-the-art research and
development facilities.
- According to a report
published in November 2023, “Adjunctive brexpiprazole 1 mg and 2 mg daily for
Japanese patients with major depressive disorder following inadequate response
to antidepressants: a phase 2/3, randomized, double-blind (BLESS) study”, an
insufficient response to antidepressants disrupts the effective treatment of
major depressive disorder (MDD). The BLESS study investigates the dosage,
efficacy, and safety of brexpiprazole as an adjunctive therapy for Japanese
patients who have not responded adequately to antidepressant therapy (ADT). The
study found that a daily dose of 1 mg of brexpiprazole was a suitable starting
point, and both 1 mg and 2 mg daily doses were effective and well tolerated as
adjunctive treatments for Japanese MDD patients with inadequate responses to
ADT.
Key Market Players
- Otsuka Pharmaceutical Co., Ltd.
- Takeda Pharmaceutical Company Limited
- Biogen Japan Ltd
- Novartis Pharma K.K.
- Abbott Japan Co., Ltd.
- Pfizer Japan Inc.
- Janssen Pharmaceuticals K.K.
- AbbVie GK
- Eli Lilly Japan K.K.
- GlaxoSmithKline K.K.
|
By Drug Type
|
By Application
|
By Region
|
- Antidepressants
- Atypical Antidepressants
- Antipsychotics
- Neuromodulators
- Others
|
|
- Hokkaido
- Tohoku
- Kanto
- Chubu
- Kansai
- Chugoku
- Shikoku
- Kyushu
|
Report Scope:
In this report, the Japan Major Depressive Disorder
(MDD) Market has been segmented into the following categories, in addition to
the industry trends which have also been detailed below:
- Japan Major Depressive
Disorder (MDD) Market, By
Drug Type:
o Antidepressants
o Atypical Antidepressants
o Antipsychotics
o Neuromodulators
o Others
- Japan Major Depressive
Disorder (MDD) Market, By
Application:
o Hospitals
o Clinics
o Others
- Japan Major Depressive
Disorder (MDD) Market, By
Region:
o Hokkaido
o Tohoku
o Kanto
o Chubu
o Kansai
o Chugoku
o Shikoku
o Kyushu
Competitive Landscape
Company Profiles: Detailed analysis of the major companies
present in the Japan Major Depressive Disorder (MDD) Market.
Available Customizations:
Japan Major Depressive Disorder (MDD) Market report
with the given market data, TechSci Research offers customizations according to
a company's specific needs. The following customization options are available
for the report:
Company Information
- Detailed analysis and
profiling of additional market players (up to five).
Japan Major Depressive Disorder (MDD) Market is
an upcoming report to be released soon. If you wish an early delivery of this
report or want to confirm the date of release, please contact us at [email protected]